Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration‐resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate‐specific antigen (PSA) levels. The goal of this post hoc analysis wa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Armstrong, Andrew J., Saad, Fred, Phung, De, Dmuchowski, Carl, Shore, Neal D., Fizazi, Karim, Hirmand, Mohammad, Forer, David, Scher, Howard I., Bono, Johann De
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://ncbi.nlm.nih.gov/pubmed/28171710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30587
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk